Implant Sciences to Demonstrate TSA-Approved QS-B220 Explosives Trace Detector at Miami International Airport West Cargo Area

Event Will Provide Information on Upcoming Changes in TSA Regulations and the Use of Explosive Trace Detection for air Cargo Screening

Marketwired

WILMINGTON, MA--(Marketwired - Sep 17, 2013) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today the Company will host explosives trace detection briefings and demonstrations of its TSA-approved QS-B220 desktop explosives trace detector at the Miami International Airport on Thursday, September 19, 2013, in the Miami-International Airport West Cargo Area Conference Room - Cargo Building 702, Suite #205. The event is open to individuals involved in air cargo security. Please contact marcom@implantsciences.com for information on how to attend.

"Explosive Trace Detection (ETD) is arguably the best air cargo security technology available today. Important changes are coming when the TSA's grandfathered list of legacy ETD systems lose their approved status on January 1, 2014. This event will provide important information for air cargo facilities looking to replace expiring systems or expand screening operations," stated Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones.

About the QS-B220 Desktop Explosives Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to currently have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 handheld explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact:


Implant Sciences Corporation
Company
Glenn Bolduc
CEO
978-752-1700
Email Contact

or

Investor
Laurel Moody
646-810-0608
Email Contact
View Comments (0)